Glutamic acid decarboxylase autoantibodies and diabetes mellitus

Mariam Balakahzde, Elene Giorgadze, Marina Lomidze


Background: Type 1 diabetes mellitus is an immune-mediated disease, which results from autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans. Glutamic acid decarboxylase of 65 kDa (GAD65) is one of the major autoantigens for type 1 diabetes mellitus. The predictive sensibility of GAD antibodies for type 1 diabetes mellitus in general population is approximately 50%.
Method: The phrases "Diabetes Mellitus" and "anti-GAD antibody ", were searched for in PubMed in Jun 2016. The results were narrowed to 12 citations after excluding non-English and duplicate reports. Clinical descriptions and outcomes were categorized and analyzed.
Conclusion: Type 1 diabetes mellitus is an immune-mediated disease, which results from autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans. Different studies revealed, that detection of GAD antibodies before clinical onset of diabetes provides evidence that these antibodies can be used as diagnostic and predictive tool for type 1 diabetes mellitus and latent autoimmune diabetes of adults.


Diabetes melitus, Type 1 diabetes, Glutamic acid decarboxylase, Autoantibodies

Full Text:



Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev.2008; 7:550-7.

Baekkeskov S, Nielsen JH, Marner B, Bild T, Ludvigsson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature.1982; 298:167-9

Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990; 347: 151-6

Sorenson RL, Garry DG, Brelje TC. Structural and Functional considerations of GABA in islets of Langerhans. Beta-cells and nerves. Diabetes. 1991; 40: 1365-74

Velloso LA, Kampe O, Hallberg A, Christmanson L, Betsholtz C, Karlssom FA. Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest. 1993; 91:2084-90

Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2010; 95:25–33

Siljander H, Veijola R, Reunanen A, Virtanen SM, Åkerblom HK, Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia. 2007; 50:2272–2275.

Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group. The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia. 2016; 59 (3): 542-9.

Giannopoulou, EZ, Winkler C, Chmiel R. et al. Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes. Diabetologia. 2015; 58: 2317-23.

Tuomi T, Groop LC, Zimmet PZ, RowleyMJ, KnowlesW, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993; 42:359 –362

Turner R., Stratton I., Horton V. UKPDS 25: autoantibodies to islet-cell cytoplasm and GAD for prediction of insulin requirement in type 2 diabetes. Lancet. 1997; 350: 1288–1293.


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)